Department of Neurosurgery, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Cell Chem Biol. 2021 Feb 18;28(2):118-120. doi: 10.1016/j.chembiol.2021.02.002.
HSP90 inhibitors are in numerous cancer clinical trials, but treatments often induce toxicity at effective dosages. In this issue of Cell Chemical Biology, Zavareh et al. (2020) serendipitously found that HSP90 inhibitors, at manageable doses, can reduce target cell expression of immune checkpoint molecules, potentially enabling improved anti-cancer immunotherapy.
HSP90 抑制剂正在进行大量的癌症临床试验，但在有效剂量下，这些治疗往往会引起毒性。在本期《细胞化学生物学》中，Zavareh 等人（2020 年）偶然发现，HSP90 抑制剂在可管理的剂量下，可以降低靶细胞中免疫检查点分子的表达，从而有可能改善癌症的免疫治疗。
